A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus

• Status: Completed
• Trial end date: 2018-08-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy and safety of nasal glucagon compared to intramuscular (IM) glucagon for treatment of insulin-induced hypoglycemia in Japanese participants with diabetes mellitus.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Glucagon; Glucagon-Like Peptide 1; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Participants with Type 1 diabetes (T1D) or Type 2 diabetes (T2D)

• Body mass Index (BMI) of 18.5 to 30.0 kilograms per meter squared (kg/m2) for T1D, or 18.5 to 35.0 kg/m2 for T2D

• Hemoglobin A1c (HbA1c) ≤10%

Exclusion Criteria:

• Have significant changes in insulin regimen and/ or unstable blood sugar control within the past 3 month

• Have received a total daily dose of insulin >1.2 units per kilogram (U/kg)